AIAP0004 Bremelanotide (PT-141)

Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Molecular formula: C50H68N14O10

Molar Mass: 1025.2

CAS number: 189691-06-3

PT-141 Structural Names: cyclo-[Nle4, Asp5, D-Phe7, Lys10]alpha-MSH-(4-10)

PT-141 is a metabolite of Melanotan 2

The Development of PT-141

PT-141 was developed from the Melanotan 2 Peptide, which underwent testing as a sunless tanning agent. In initial testing,

Melanotan 2 did induce tanning, but additionally caused sexual arousal and spontaneous erections as unexpected side effects in nine out of the ten original male volunteer test subjects. Palatin completed patient treatment in its Phase 2B clinical trial in premenopausal women with FSD Primary data analysis and announcement of top-line results anticipated in first-half of fourth quarter of calendar year 2012. In studies, PT-141 was shown to be effective in treating sexual dysfunction in both men (erectile dysfunction or impotence) and women (sexual arousal disorder). Unlike other related medications, it does not act upon the vascular system, but directly increases sexual desire via the nervous system.